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Abstract
Post-stroke dementia is common but has heterogenous mechanisms that are not fully understood, particularly in patients 
with atrial fibrillation (AF)-related ischaemic stroke or TIA. We investigated the relationship between MRI small-vessel 
disease markers (including a composite cerebral amyloid angiopathy, CAA, score) and cognitive trajectory over 12 months. 
We included patients from the CROMIS-2 AF study without pre-existing cognitive impairment and with Montreal Cognitive 
Assessment (MoCA) data. Cognitive impairment was defined as MoCA < 26. We defined “reverters” as patients with an 
“acute” MoCA (immediately after the index event) score < 26, who then improved by ≥ 2 points at 12 months. In our cohort 
(n = 114), 12-month MoCA improved overall relative to acute performance (mean difference 1.69 points, 95% CI 1.03–2.36, 
p < 0.00001). 12-month cognitive impairment was associated with increasing CAA score (per-point increase, adjusted OR 
4.09, 95% CI 1.36–12.33, p = 0.012). Of those with abnormal acute MoCA score (n = 66), 59.1% (n = 39) were “reverters”. 
Non-reversion was associated with centrum semi-ovale perivascular spaces (per-grade increase, unadjusted OR 1.83, 95% 
CI 1.06–3.15, p = 0.03), cerebral microbleeds (unadjusted OR 10.86, 95% CI 1.22–96.34, p = 0.03), and (negatively) with 
multiple ischaemic lesions at baseline (unadjusted OR 0.11, 95% CI 0.02–0.90, p = 0.04), as well as composite small-vessel 
disease (per-point increase, unadjusted OR 2.91, 95% CI 1.23–6.88, p = 0.015) and CAA (per-point increase, unadjusted 
OR 6.71, 95% CI 2.10–21.50, p = 0.001) scores. In AF-related acute ischaemic stroke or TIA, cerebral small-vessel disease 
is associated both with cognitive performance at 12 months and failure to improve over this period.
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Introduction
Post-stroke dementia is common [30] but has heterog-
enous mechanisms that are not fully understood. Early 
post-stroke dementia (within 6  months) is associated 
with factors relating to brain resilience and the index 
stroke lesion, whereas delayed-onset post-stroke demen-
tia is more associated with cerebral small-vessel diseases 
[23]. This appears to be the case for both ischaemic and 
haemorrhagic stroke; dementia after ischaemic intracer-
ebral events (stroke or transient ischaemic attacks, TIA) 
is associated with white-matter hyperintensities, lacu-
nes and cortical atrophy [1, 24], and markers of cerebral 
amyloid angiopathy (CAA) are associated with dementia 
after intracerebral haemorrhage [25]. The contribution of 
small-vessel disease to post-stroke dementia in patients 
with atrial fibrillation (AF)-related ischaemic stroke or 
TIA is unknown. AF is recognised as an independent risk 
factor for dementia [20]; proposed mechanisms include 
silent brain infarction from recurrent embolization, cer-
ebral hypoperfusion, chronic inflammation and endothelial 
dysfunction, or progression of pre-existing cerebrovascu-
lar or neurodegenerative processes [31], but information 
on the imaging associations of post-stroke dementia in this 
context remains limited.
The natural history of post-stroke dementia is further 
complicated by the fact that cognitive performance imme-
diately after a stroke might not be representative of later 
cognition, as performance might improve; this occurs both 
acutely, where the initial assessment might be influenced 
by delirium, but also over longer time periods [2, 10, 17, 
19, 29]. The Montreal Cognitive Assessment (MoCA) 
appears to be a sensitive cognitive screen for identifying 
these changes [34], and there has been recent interest in 
identifying the characteristics of so-called “reverters”, 
who demonstrate improvements in their cognitive perfor-
mance over time [27, 34, 38, 43].
We investigated cognitive trajectory in patients with 
AF-related ischaemic stroke or TIA. Our objectives were: 
(1) to describe the changes in MoCA that occur between 
acute (immediately post ischaemic event) and 12 month 
assessment, (2) to investigate the clinical and radiologi-
cal associations of MoCA-defined cognitive impairment 
at 12 months, and (3) to describe the clinical and imaging 
profile of reverters and non-reverters.
Materials and methods
Patient selection
This is a subgroup analysis of the CROMIS-2 AF study, 
the protocol for which has been described [7, 41]. Briefly, 
this was a multi-centre prospective observational study of 
adults (aged 18 years or above) presenting with ischae-
mic cardioembolic stroke or TIA with non-valvular atrial 
fibrillation (confirmed by electrocardiography), who were 
eligible to start anticoagulation following their ischaemic 
event [7, 41]. Patients who could not have an MRI scan, 
had contraindications to anticoagulation, or had previously 
received therapeutic anticoagulation, were excluded [7, 
41]. The study was approved by the National Research 
Ethics Service (IRAS reference 10/H0716/61), and written 
informed consent was obtained for each patient.
We excluded patients with known documented diagnosis 
of dementia or cognitive impairment, or 16-item IQCODE 
(Informant Questionnaire for Cognitive Decline in the 
Elderly) score > 3.3 [16] at study entry (Fig. 1). We com-
pared characteristics of eligible (those with 12 month MoCA 
data) and excluded patients (those without) to assess selec-
tion bias.
Fig. 1  Description of study population
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Cognitive measures
The “acute” MoCA was collected immediately after the 
index ischaemic event. All participating centres were invited 
to collect additional MoCA data at 12 months (“12 month 
MoCA”) following study entry; 20 centres agreed to con-
tribute to this substudy. A MoCA score < 26 was used to 
define cognitive impairment [26]. “Reverters” were defined 
as patients with an acute MoCA score < 26, who demon-
strated an improvement of ≥ 2 points at 12 months, and 
patients with an acute MoCA score < 26 who did not show 
this improvement were defined as “non-reverters”. These 
thresholds are based on definitions from previously pub-
lished work [27, 34].
Imaging
Imaging was undertaken locally at each study centre in 
accordance with a standardised protocol including axial 
T2, T2*-GRE, diffusion-weighted imaging, coronal T1 and 
FLAIR images [7]. Sequence parameters were specified 
for T2*-GRE [7]; the remaining sequences were obtained 
according to local protocols.
Neuroimaging analysis was carried out by two clinical 
research associates trained in rating structural markers of 
small-vessel disease and blinded to clinical details. Each 
structural marker was rated by a single rater, and all struc-
tural markers of cerebral small-vessel disease were rated in 
accordance with consensus criteria [40], and, where pos-
sible, the hemisphere contralateral to the acute stroke was 
preferentially counted.
Previous cortical infarcts were identified using T2 and 
FLAIR sequences and confirmed as non-acute through com-
parison with diffusion-weighted images (DWI). Lacunes were 
identified and counted on T2 and FLAIR sequences using defi-
nitions from the STRIVE criteria [40]. White-matter hyper-
intensities in deep (dWMH) and periventricular (pvWMH) 
distributions were rated on T2 and FLAIR sequences using the 
Fazekas scale [11, 12]. MRI-visible perivascular spaces in the 
basal ganglia (BG-PVS) and centrum semi-ovale (CSO-PVS) 
were rated on T2 and FLAIR sequences using a previously 
described validated visual rating scale [9, 22]. Medial tempo-
ral atrophy (MTA) was rated on T1 or FLAIR coronal images 
using the Scheltens visual scale [15]. Global cortical atrophy 
(GCA) was rated with the Pasquier scale [28] using axial T1, 
FLAIR or inverted T2 images. Cortical superficial siderosis 
(cSS) was identified on T2*-GRE sequences and classified as 
either focal, involving three or fewer sulci, or disseminated, 
involving four or more sulci [5]. Cerebral microbleeds (CMB) 
were rated using T2*-GRE sequences using the Microbleed 
Anatomical Rating Scale (MARS) [13]. Composite SVD [36, 
37] and CAA [6] scores were determined using previously 
described scales.
Acute DWI lesions were defined as areas bright on the 
B1000 and dark on the corresponding ADC map; the side of 
the lesion, presence of single or multiple acute lesions, and 
evidence of cortical involvement were recorded. Evidence 
of haemorrhagic transformation was rated using the ECASS 
classification [32] using T2*-GRE sequences.
Statistics
We compared baseline clinical, demographic and imaging 
findings in patients with and without MoCA-defined cogni-
tive impairment at 12 months, and for reverters compared 
with non-reverters. For all continuous variables, data were 
reviewed for normality, and if normally distributed, the inde-
pendent t-test was used. If variables were ordinal or not nor-
mally distributed, the non-parametric Mann–Whitney U test 
was used. Chi-squared or Fisher’s exact tests were used for 
categorical variables. Performances of acute and 12 month 
MoCA were compared using paired t tests (mean scores) or 
McNemar’s test (proportion impaired).
The results of univariate comparisons were used to iden-
tify variables for inclusion in multivariable logistic regres-
sion models; all variables with p < 0.20 were included in the 
adjusted analyses except for situations where variables both 
described the same phenomenon (for example, clinical his-
tory of previous ischaemic events and imaging evidence of a 
previous cortical infarct). Adjusted models considered only 
a single neuroimaging marker at a time. Given that these 
analyses were exploratory, we did not make an adjustment 
for multiple testing.
Statistical analysis was performed (GB) using Stata (Ver-
sion 11.2).
Results
Participants
383 patients were recruited from the 20 sites participating 
in the MoCA substudy: 286 patients were eligible for this 
substudy, of whom 117 had 12 month cognitive data avail-
able (Fig. 1). The characteristics of those with 12 month 
MoCA data and those without (i.e. those excluded from this 
substudy) are shown in Table 1. Those included within the 
analysis had a mean age of 73.1 years; 45 (38.5%) were 
female, and the median NIHSS on admission was 3.5.
Comparison of acute and 12 months MoCA 
performance
Acute MoCA data were available for 114 patients with 
12 month MoCA data (Fig. 2). The median time to acute 
1253Journal of Neurology (2019) 266:1250–1259 
1 3
MoCA assessment was 4 days (IQR 2–8 days). Overall, there 
was an improvement at 12 months (mean difference 1.69 
points where maximum score is 30, p < 0.00001; Table 2). 
Scores improved across all subdomains except for attention 
(which showed a deterioration) and were statistically sig-
nificant for visuo-executive function (mean difference 0.23 
points, p = 0.0470), abstraction (mean difference 0.14 points, 
p = 0.0176) and delayed recall (mean difference 0.62 points, 
p = 0.0002).
We also considered whether the proportion of participants 
impaired across domains (defined as scoring less than full 
marks) changed with time (Table 2). Fewer patients demon-
strated MoCA impairments at 12 months (51.3% vs 57.9%, 
p = 0.0719), and there were lower proportions of impaired 
participants across all domains; this was statistically signifi-
cant for language (48.7% vs 59.7%, p = 0.0269), and abstrac-
tion (22.2% vs 31.6%, p = 0.0233).
Clinical and imaging associations of cognitive 
impairment 12 months following index ischaemic 
event
In our cohort, 51.3% (n = 60) had an abnormal MoCA score 
(< 26) at 12 months. When comparing those with and with-
out MoCA-defined cognitive impairment at 12 months, 
those with impairment were older (mean age 75.6 years vs 
70.5 years, p = 0.0022), had fewer years of education (mean 
15.9 years vs 17.7 years, p = 0.0077), had a higher admis-
sion NIHSS (median score 5.5 vs 2, p = 0.0060), lower acute 
MoCA score (median 22 vs 27, p < 0.00001) and higher dis-
charge mRS (median score 2 vs 1, p = 0.0004). In a multivar-
iable logistic regression analysis including these variables, 
only acute MoCA score remained associated with MoCA 
impairment at 12 months (per-point increase, OR 0.73, 95% 
CI 0.59–0.91, p = 0.005).
Patients with cognitive impairment at 12 months had 
higher grades of pvWMH (IQR 0–1 vs 0–0, p = 0.0545) and 
Table 1  Baseline characteristics 
of included and excluded 
patients
Percentage values were calculated using the total number of patients for whom data were available as the 
denominator. p values are from independent t-tests (age, educational age, discharge mRS), Mann–Whitney 
U test (NIHSS, acute MoCA score), Fisher’s exact test (heart failure) or Chi-squared tests (remainder)
AF Atrial fibrillation, IQR interquartile range, MoCA Montreal cognitive assessment, mRS modified Rankin 
scale, NIHSS National Institutes of Health Stroke Scale, SD standard deviation
Included (n = 117) Excluded (n = 169) p value
Age (years), mean (SD) 73.1 (9.1) 74.2 (10.7) 0.3757
Sex, female, n (%) 45 (38.5) 69 (40.8) 0.688
Hypertension, n (%) 60 (52.2) 100 (59.2) 0.243
Hypercholesterolaemia, n (%) 51 (44.4) 83 (49.7) 0.376
Diabetes mellitus, n (%) 11 (9.5) 33 (19.5) 0.021
Smoking
 Never 51 (44.0) 77 (45.6) 0.960
 Ex-smoker 54 (46.6) 77 (45.6)
 Current smoker 11 (9.5) 15 (8.9)
Heart failure, n (%) 4 (3.5) 9 (5.4) 0.569
AF prior to study entry, n (%) 28 (23.9) 61 (36.3) 0.027
Educational age (years), mean (SD) 16.8 (3.5) 16.0 (2.5) 0.0288
NIHSS, median (IQR) 3.5 (2–9) 5.5 (2–11) 0.0210
Acute MoCA score, median (IQR) 25 (21–27) 23 (18–26) 0.0091
Discharge mRS, median (IQR) 1 (0–2) 1 (1–3) 0.0321
Further intracerebral event within 
12 months of study entry, n (%)
6 (5.1) 9 (5.3) 0.941
Fig. 2  Distribution of acute and 12  months MoCA scores. Each 
patient is shown by a single diamond; the data have been jittered to 
show individual points. The line of equality is shown in red
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had higher CAA scores (median score 0.5 vs 0, p = 0.0005). 
There were no statistically significant differences between 
the two groups in the imaging features of the index ischae-
mic lesion (presence of acute DWI lesion at study entry, 
side of index lesion, presence of multiple index lesions on 
DWI, presence of a cortical lesion, evidence of haemor-
rhagic transformation). In adjusted analyses (adjusted for 
age, educational age, discharge mRS and acute MoCA 
score), cognitive impairment at 12 months remained asso-
ciated with CAA score (per-point increase, OR 4.09, 95% 
CI 1.36–12.33, p = 0.012) but not pvWMH grade (OR 1.15, 
95% CI 0.54–2.44, p = 0.725).
MoCA trajectory
In this cohort, 66 patients had an acute MoCA score below 
26; of these, 59.1% (n = 39) were “reverters” (Fig. 3). Non-
reverters had higher acute MoCA scores (median 24 vs 21, 
p = 0.0002) and lower 12-month MoCA scores (median 23 
vs 25, p = 0.0008); there were no other clinical or demo-
graphic (including years of education) differences between 
the two groups.
The imaging characteristics of reverters and non-revert-
ers are shown in Table 3. Non-reverters had lower baseline 
pvWMH grade (IQR 0–0 vs 0–1, p = 0.0752), but higher 
CSO-PVS grade (median grade 2 vs 1, p = 0.0306), and 
were more likely to have cerebral microbleeds (22.2% vs 
2.6%, p = 0.016) and in particular, strictly lobar microbleeds 
(14.8% vs 0.0%, p = 0.024). Non-reverters also had a higher 
composite SVD (mean 0.88 vs 0.27, p = 0.0046) and CAA 
(mean 0.80 vs 0.25, p = 0.0007) scores. In unadjusted logis-
tic regression analyses (Table 4), non-reversion remained 
positively associated with CSO-PVS grade (per-grade 
increase, OR 1.83, p = 0.029), cerebral microbleed pres-
ence (OR 10.86, p = 0.032), SVD score (per-point increase, 
OR 2.91, p = 0.015) and CAA score (per-point increase, OR 
6.71, p = 0.001), and negatively associated with the pres-
ence of multiple lesions at study entry (OR 0.11, p = 0.040). 
Table 2  Comparison of MoCA performance acutely (median 4 days following ischaemic event) and at 12 months
Impairment was defined as scoring less than full marks in a given domain; MoCA impairment was defined as previously (score < 26). Percentage 
values were calculated using the total number of patients for whom data were available as the denominator. For the comparison of mean scores, 
p values are from paired t tests, and for the comparison of proportion impaired, McNemar’s test was used
CI Confidence intervals, MoCA Montreal Cognitive Assessment, SD standard deviation
Comparison of means Comparison of proportions
Maximum 
achievable 
score
Acute MoCA 
(n = 114); mean 
score (SD)
12 month 
MoCA 
(n = 117); mean 
score (SD)
Mean difference 
(95% CI)
p value Acute MoCA 
(n = 114); 
impaired, n (%)
12 month 
MoCA 
(n = 117), 
impaired, n (%)
p value
Total score 30 23.55 (4.95) 25.25 (3.88) 1.69 (1.03–2.36) < 0.00001 66 (57.9) 60 (51.3) 0.0719
Visuo-executive 5 3.77 (1.38) 4.00 (1.13) 0.23 (0.00–0.45) 0.0470 72 (63.2) 69 (59.0) 0.2888
Naming 3 2.75 (0.61) 2.82 (0.49) 0.07 (− 0.05 to 
0.19)
0.2399 22 (19.3) 17 (14.5) 0.3173
Attention 6 4.98 (1.49) 4.70 (1.60) − 0.28 (− 0.05 to 
0.61)
0.0964 61 (53.5) 54 (46.2) 0.1228
Orientation 6 5.58 (1.06) 5.71 (0.73) 0.13 (− 0.05 to 
0.32)
0.1628 25 (21.9) 24 (20.5) 0.5050
Language 3 2.11 (0.91) 2.25 (0.96) 0.13 (− 0.05 to 
0.32)
0.1591 68 (59.7) 57 (48.7) 0.0269
Abstraction 2 1.58 (0.68) 1.72 (0.59) 0.14 (0.02–0.26) 0.0176 36 (31.6) 26 (22.2) 0.0233
Delayed recall 5 2.34 (1.62) 2.96 (1.53) 0.62 (0.31–0.94) 0.0002 102 (89.5) 98 (83.8) 0.1444
Fig. 3  Distribution of acute and 12 months MoCA scores for revert-
ers and non-reverters. Each patient is shown by a single symbol, as 
indicated by the key; the data have been jittered to show individual 
points. The line of equality is shown in red
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Table 3  Comparison of imaging 
characteristics of reverters vs 
non-reverters
Percentage values were calculated using the total number of patients for whom data werer available as the 
denominator. p values are from Mann–Whitney U tests (where median and IQR are given), Chi-squared 
tests (acute DWI lesion at study entry) or Fisher’s exact test (remainder)
BG-PVS MRI-visible perivascular spaces in the basal ganglia, CMB cerebral microbleed, CSO MRI-visible 
perivascular spaces in the centrum semi-ovale, DWI diffusion-weighted imaging, dWMH deep white-matter 
hyperintensities, GCA global cortical atrophy, IQR interquartile range, MoCA Montreal cognitive assess-
ment, MTA medial temporal atrophy, pvWVH periventricular hyperintensities, SD standard deviation
Reverters Non-reverters p value
n (%) 39 (59.1) 27 (40.9) –
Structural imaging markers at study entry
 Imaging evidence of previous cortical infarct, n (%) 3 (7.7) 4 (14.8) 0.432
 Lacunes, presence, n (%) 5 (12.8) 5 (20.8) 0.485
 pvWMH grade, median (IQR) 0 (0–1) 0 (0–0) 0.0752
 dWMH grade, median (IQR) 1 (0–1) 0 (0–1) 0.3217
 CSO-PVS grade, median (IQR) 1 (1–2) 2 (1–3) 0.0306
 BG-PVS grade, median (IQR) 1 (1–1) 1 (1–1) 0.1221
 MTA grade, median (IQR) 1 (0–1) 1 (0–1) 0.7561
 GCA grade, median (IQR) 1 (0–1) 1 (0–1) 0.9943
 CMB, presence, n (%) 1 (2.6) 6 (22.2) 0.016
 Strictly lobar CMB, n (%) 0 (0.0) 4 (14.8) 0.024
 Composite SVD score, median (IQR)
  Median (IQR) 0 (0–0) 1 (0–1) 0.0046
  Mean (SD) 0.27 (0.61) 0.88 (0.93)
 Composite CAA score, median (IQR)
  Median (IQR) 0 (0–0.5) 1 (0–1) 0.0007
  Mean (SD) 0.25 (0.44) 0.80 (0.62)
Imaging features of index ischaemic event
 Acute DWI lesion at study entry, n (%) 32 (82.1) 19 (76.0) 0.557
 Side of index lesion, n (%)
  Left 11 (35.5) 6 (31.6) 0.249
  Right 16 (51.6) 13 (68.4)
  Bilateral 4 (12.9) 0 (0.0)
 Presence of multiple lesions, n (%) 11 (34.4) 1 (5.3) 0.020
 Cortical lesion, n (%) 21 (65.6) 14 (73.7) 0.756
 Evidence of haemorrhagic transformation, n (%) 8 (20.5) 2 (8.7) 0.298
Table 4  Unadjusted and 
adjusted logistic regression 
analyses for predictors of non-
reversion
Each model considered one imaging marker at a time
BG-PVS MRI-visible perivascular spaces in the centrum semi-ovale, CAA cerebral amyloid angiopathy, CI 
confidence interval, CMB cerebral microbleed, CSO-PVS MRI-visible perivascular spaces in the centrum 
semi-ovale, MoCA Montreal cognitive assessment, pvWMH periventricular hyperintensities, SVD small-
vessel disease
Unadjusted Adjusted for acute MoCA 
score
OR (95% CI) p value OR (95% CI) p value
pvWMH (per-grade increase) 0.41 (0.12–1.35) 0.143 0.50 (0.15–1.68) 0.264
CSO-PVS (per-grade increase) 1.83 (1.06–3.15) 0.029 1.96 (1.05–3.66) 0.035
BG-PVS (per-grade increase) 2.60 (0.74–9.19) 0.137 2.26 (0.63–8.02) 0.209
CMB (presence) 10.86 (1.22–96.34) 0.032 9.36 (0.92–95.34) 0.059
SVD score (per-point increase) 2.91 (1.23–6.88) 0.015 2.47 (1.02–6.00) 0.046
CAA score (per-point increase) 6.71 (2.10–21.50) 0.001 6.70 (1.88–23.98) 0.003
Presence of multiple lesions at study entry 0.11 (0.02–0.90) 0.040 0.11 (0.01–1.01) 0.051
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Similar associations were observed in analyses adjusted for 
MoCA score (Table 4).
Discussion
MoCA-defined cognitive impairment at 12 months is com-
mon, observed in approximately half of our cohort, and 
associated with factors relating to brain resilience (age, 
educational age) and stroke severity (acute MoCA score, 
NIHSS, discharge mRS), as well as increases in a compos-
ite CAA score. Overall, we found that MoCA performance 
at 12 months improves compared with acute performance, 
and we show that the presence of structural imaging mark-
ers of small-vessel disease (CSO-PVS, cerebral micro-
bleeds, composite SVD and CAA scores) is associated with 
non-reversion.
Our use of composite scores for the two most com-
mon small-vessel diseases provides new perspectives on 
the small-vessel mechanisms which might underlie post-
stroke dementia. Composite scores are hypothesised to 
better reflect overall pathological burden and have shown 
associations with a number of clinical measures including 
cognitive performance [8, 18, 35, 36, 39]. In our study, we 
observed an association of 12-month cognitive performance 
with the composite CAA score. This score includes non-
haemorrhagic markers of CAA such as CSO-PVS and WMH 
which do not feature in the current diagnostic criteria for 
CAA [21], and which might have more relevance in non-
haemorrhagic patient populations. The association of CAA 
with dementia following intracerebral haemorrhage has been 
described [25], as have associations between strictly lobar 
microbleeds and executive function in patients with ischae-
mic stroke or TIA [14]. Whilst our finding that CAA score 
is associated with 12-month MoCA impairment should be 
interpreted with caution, given the low prevalence of haem-
orrhagic markers and the relatively small size of the cohort, 
it might provide further evidence that imaging markers of 
CAA are associated with cognitive performance beyond 
intracerebral haemorrhage, a finding already observed in 
non-haemorrhagic memory clinic populations [33, 42].
Our observation that overall cognitive performance 
can improve with time following an ischaemic event is in 
keeping with data from previous studies [2, 10, 17, 19, 
29], as are the significant domain specific improvements 
in visuo-executive function, abstraction and delayed recall 
[27, 34]. As well as improvements in raw scores, we also 
found that levels of impairment were lower at 12 months for 
most domains. However, we did note that for a number of 
domains, whilst raw scores improved significantly, patients 
remained impaired range (as we defined it). This highlights 
the difficulties in quantifying deficits when considering indi-
vidual domains.
We also describe the characteristics of patients with 
impaired acute performance who demonstrate an improve-
ment of two or more points—so-called “reverters”[27, 34]—
and those who do not. Whilst use of the term “reverter” has 
been criticised for suggesting that cognitive performance 
returns to normal [27], it is useful as a standardised method 
for defining improvement. Whilst we did not find any clini-
cal or demographic differences between reverters and non-
reverters (except for those relating to MoCA scores), there 
were imaging differences. Non-reverters appeared to have 
more evidence of small-vessel disease (CSO-PVS, cerebral 
microbleeds, and higher composite SVD and CAA scores), 
and were less likely to have had multiple acute DWI lesions 
at study entry. As discussed above, the association between 
both multiple lesions and lower acute MoCA scores amongst 
the reverters might suggest that multiple lesions are more 
likely to result in an acute reversible cognitive impair-
ment—although the acute disturbance in this cohort does 
not seem to be typical for delirium, given the lack of atten-
tional improvement with time. Replication of this work in 
larger cohorts will be important for confirming and better 
quantifying these observations.
The strengths of this study are its multicentre prospec-
tive design, and the detailed clinical and radiological 
descriptions available for the study participants. However, 
there are also some limitations. Firstly, only a subset of 
centres collected 12-month MoCA data, and even within 
these centres MoCA data were not collected for all poten-
tially eligible participants. The excluded patients had more 
comorbidities, lower educational age, more severe ischae-
mic events (as defined by NIHSS and discharge mRS) and 
had lower acute MoCA scores, all of which are associated 
with poorer cognitive outcome at 12 months. Given this, 
and the fact that our cohort tended to have milder strokes 
(median NIHSS 3.5), the cognitive performance of our 
cohort might be better than expected and not representa-
tive of all cardioembolic ischaemic stroke or TIA cohorts. 
Additionally, we were unable to account for patients who 
were aphasic; this should be considered in the interpre-
tation of our results. We note that group sizes for some 
analyses are small and the prevalence of haemorrhagic 
markers in our cohort was low; in view of this, these 
results should be interpreted cautiously. Our modest group 
sizes also precluded further subdivision into the reverter 
and non-reverter groups; in particular, a comparison of 
non-reverters with stable cognition vs those demonstrat-
ing further decline would be of interest, and an important 
area for future work. Cognitive assessments acutely after 
an ischaemic event period can be difficult to interpret, as 
cognitive performance can be influenced by intercurrent 
illness (such as coexisting infection, as one example) or 
complications relating to the ischaemic event itself (for 
example, seizures). Whilst we acknowledge that a slightly 
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delayed assessment (for example, 2–4  weeks after an 
ischaemic event), might avoid these complicating factors, 
in routine clinical practice the first measurement of cog-
nitive performance (using the MoCA and other tools) is 
often in the acute period, as in our study; the implications 
of early assessments are therefore of relevance. Finally, we 
only used a single measure (the MoCA) to estimate cog-
nitive performance at a single time point; the MoCA has 
some intrinsic limitations, including the fact that it is pri-
marily a screening tool and thus likely underestimates the 
severity and breadth of cognitive impairment that result 
from stroke [3, 4]. The absence of data on MoCA perfor-
mance at additional time points, both before 1 year (for 
example, at 3 or 6 months) and beyond this (for example, 
at 2 years), is a further limitation; this would allow us to 
better define post-event cognitive trajectory, and the lack 
of assessment at additional time points is a limitation of 
our study design. Nevertheless, the positive findings and 
associations found show some promise that it might be a 
useful tool for monitoring for change over time.
We conclude that MoCA-defined cognitive impairment 
12 months following an ischaemic event is common, and 
that structural imaging features of small-vessel disease 
appear associated both with deficits and a lack of improve-
ment at 12 months. Further work that clarifies the role of 
small-vessel diseases in this context will be essential for 
refining future cognitive rehabilitation strategies.
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